NBY NovaBay Pharmaceuticals
- 0.0866
- -0.0044-4.84%
NovaBay Pharmaceuticals News
NovaBay Pharmaceuticals Announces Record Ordered Product Sales Of Avenova-Branded Products Through Amazon For April 2024 Increased By More Than 20% Compared With April 2023
Ordered product sales of Avenova-branded products on Amazon.com set back-to-back records in March and April 2024Enhanced marketing program provides potential for additional growth in the U.S. dry eye
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community
NovaBay Pharmaceuticals Receives NYSE Notice for Compliance
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity.
NovaBay Pharmaceuticals Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Preliminary Q1 Net Revenue Results.
NovaBay Pharmaceuticals Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Preliminary Q1 Net Revenue Results.
NovaBay Pharmaceuticals Reports Preliminary Q1 FY24 Net Revenue For Its Eyecare And Wound Care Business Of $2.6M, Up 13% YoY
NovaBay Pharmaceuticals Reports Preliminary Q1 FY24 Net Revenue For Its Eyecare And Wound Care Business Of $2.6M, Up 13% YoY
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript
Earnings Call Summary | NovaBay Pharmaceuticals(NBY.US) Q4 2023 Earnings Conference
The following is a summary of the NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript:Financial Performance:NovaBay reported a total Q4 2023 sales net of $3.7 million, marking a 2% in
NovaBay Pharmaceuticals: Q4 Earnings Insights
NovaBay Pharmaceuticals (AMEX:NBY) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsNovaBay Pharmaceuticals bea
NovaBay Pharmaceuticals Q4 EPS $(0.21) Beats $(0.30) Estimate, Sales $3.73M Beat $3.40M Estimate
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30 percent. This is a 85.71 percent increase over losses of $(
NovaBay GAAP EPS of -$1.33, Revenue of $3.7M
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, Vs. Street Est of $3.4M
04:09 PM EDT, 03/26/2024 (MT Newswires) -- Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M
NovaBay 4Q Loss $4.11M >NBY
NovaBay 4Q Loss $4.11M >NBY
Press Release: NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results -- Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales fr
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBayPharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market
Novabay Reported Preliminary 2023 Sales Of $14.7M, Consisting Of $3.6M From Its DERMAdoctor Skincare Segment And $11.1M From Its Eyecare And Wound Care Segment Versus Consensus Of $14.40M
Operating loss for the 2023 fiscal year is expected to be approximately $7.4 million, which includes a $3.8 million loss in the DERMAdoctor skincare segment. The DERMAdoctor skincare segment loss incl
NovaBay Expects to Close the Transaction Before the End of the 1Q of 2024 >NBY
NovaBay Expects to Close the Transaction Before the End of the 1Q of 2024 >NBY
NovaBay To Sell Its DERMAdoctor Skincare Business Including All Pdt Inventory for $1M in Cash >NBY
NovaBay To Sell Its DERMAdoctor Skincare Business Including All Pdt Inventory for $1M in Cash >NBY
NovaBay Cash as of Dec 31 Was $3.1M >NBY
NovaBay Cash as of Dec 31 Was $3.1M >NBY
Analysis
Price Target
No Data
